Navigation Links
Canadian Marketing and Sales Effort for Labopharm's Once-Daily Tramadol Product to Expand Significantly
Date:2/1/2008

- Labopharm's Canadian Marketing Partner, Paladin, Enters Into Co-

Promotion Agreement with Nycomed Canada -

LAVAL, QC, Feb. 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS) today announced that its Canadian licensing and distribution partner for its once-daily tramadol product (Tridural(TM)), Paladin Labs Inc. (TSX: PLB), has entered into a co-promotion agreement for Tridural(TM) with Nycomed Canada Inc. The agreement will double the number of primary care sales representatives promoting Tridural(TM) in Canada.

"The addition of Nycomed's sales force to that of Paladin will significantly expand the marketing and sales effort behind our product," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We are very pleased with the continued penetration of Tridural(TM) into the Canadian pain market. While still relatively early in the launch, growth indicators and feedback from the market are very strong."

Under the co-promotion agreement between Paladin and Nycomed, Nycomed will share brand responsibilities and expenses with Paladin and will deploy a national primary care sales force to promote Tridural(TM). Paladin will continue to manage distribution of Tridural(TM) and will also continue to promote Tridural(TM) using its primary care sales force.

Labopharm entered into a licensing and distribution agreement for its once-daily tramadol product for Canada with Paladin in July 2007. Paladin subsequently launched the product to the Canadian market in September 2007.

About Tridural(TM)

Tridural(TM) is a unique treatment option developed as a first-line therapy for adult patients with moderate pain who require treatment for several days or more that provides 24-hour pain relief from a single tablet taken once-daily. Tridural(TM) is based on Labopharm's proprietary controlled-release technology, Contramid(R), and a novel dual matrix delivery system that facilitates both rapid and sustained drug release, maintaining therapeutic blood levels of tramadol for a full 24-hour period. Tridural(TM) offers physicians and patients greater treatment flexibility based on its relatively rapid two-day titration schedule, which could help patients reach their optimum daily dose faster than any other approved once-daily tramadol product and quickly achieve effective pain relief. In addition, Tridural(TM) has a demonstrated safety profile based on clinical trial experience of more than 2,400 patients globally and almost two years of commercial experience.

About the Global Commercialization Program for Labopharm's Once-Daily

Tramadol Product

Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 10 countries, including the five largest markets in Europe and Canada, and is approved in 15 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distributions in place for more than 50 markets worldwide.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the price of the Company's shares, the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
3. New Canadian study finds drug coated heart stents to be safe:
4. Canadians welcome HPV vaccine -- but not at any price
5. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
6. Canadian Pacific and Mayo Clinic Build Understanding and Commit to Ongoing Dialogue
7. Map the Canadian Healthcare IT Market with the New HIMSS Analytics Canadian Database(SM)
8. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Fitness Champion Natalie Waples to be Spokesperson for Natural Nutrition International Direct Marketing Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: